CSL Limited - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Detailed information on CSL Limited required for business and competitor intelligence needs
A study of the major internal and external factors affecting CSL Limited in the form of a SWOT analysis
An in-depth view of the business model of CSL Limited including a breakdown and examination of key business segments
Intelligence on CSL Limited’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
News about CSL Limited, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
CSL (or 'the group') is a leading global provider of biotherapies to treat and prevent serious and rare medical conditions. The group operates globally through its human health businesses that include the operations of CSL Behring, CSL Bioplasma and CSL Biotherapies. CSL is headquartered in Victoria, Australia, and employed about 11,285 people as of June 30, 2013. The group's recorded revenues of $4,950.4 million during the financial year ended June 2013 (FY2013), an increase of 7.2% over FY2012. The operating profit of the group's was $1,515.1 million in FY2013, an increase of 15.6% over FY2012. The net profit attributable to members of the parent company was $1,216.3 million in FY2013, an increase of 18.8% over FY2012.
Reasons to Purchase:
Gain understanding of CSL Limited and the factors that influence its strategies
Track strategic initiatives of the company and latest corporate news and actions
Assess CSL Limited as a prospective partner, vendor or supplier
Support sales activities by understanding your customers' businesses better
Stay up to date on CSL Limited’s business structure, strategy and prospects